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ABSTRACT The cholangiopathies are a group of hepato-
biliary diseases in which intrahepatic bile duct epithelial cells, or
cholangiocytes, are the target for a variety of destructive pro-
cesses, including immune-mediated damage. We tested the hy-
pothesis that cholangitis could be induced in rodents by immu-
nization with highly purified cholangiocytes. Inbred Wistar rats
were immunized with purified hyperplastic cholangiocytes iso-
lated after bile duct ligation from either syngeneic Wistar or
allogeneic Fischer 344 rats; control rats were immunized with
bovine serum albumin (BSA) or hepatocytes. After immunization
with cholangiocytes, recipient animals developed histologic evi-
dence of nonsuppurative cholangitis without inflammation in
other organs; groups immunized with BSA or hepatocytes
showed no cholangitis. Immunohistochemical studies revealed
that portal tract infiltrates around bile ducts consisted of
CD3-positive lymphocytes, some of which expressed major his-
tocompatibility complex class II antigen; B cells and exogenous
monocytes/macrophages were essentially absent. Transfer of
unfractionated Con-A-stimulated spleen cells from cholangio-
cyte-immunized (but not BSA-immunized) rats into recipients
also caused nonsuppurative cholangitis. Moreover, these spleno-
cytes from cholangiocyte-immunized (but not BSA-immunized)
rats were cytotoxic in vitro for cultured rodent cholangiocytes; no
cytotoxicity was observed against a rat hepatocyte cell line. Also,
a specific antibody response in sera of cholangiocyte-immunized
rats was demonstrated by immunoblots against cholangiocyte
proteins. Finally, cholangiograms in cholangiocyte-immunized
rats showed distortion and tortuosity of the entire intrahepatic
biliary ductal system. This unique rodent model of experimental
cholangitis demonstrates the importance of immune mecha-
nisms in the pathogenesis of cholangitis and will prove useful in
exploring the mechanisms by which the immune system targets
and damages cholangiocytes.
Human cholangiopathies represent a diverse group of liver
diseases in which the intrahepatic bile duct epithelial cell, or
cholangiocyte, is thought to be the target of destruction (1).
These diseases can be grouped into two general categories:
non-immune-mediated and immune-mediated. The former
result from a variety of causes, including genetic predisposition
(e.g., cystic fibrosis), infections (e.g., AIDS cholangiopathy), or
ischemia; the latter include graft-versus-host disease (GVHD),
liver allograft rejection, primary biliary cirrhosis (PBC), and
primary sclerosing cholangitis (PSC). Immune-mediated
cholangiopathies are progressive diseases which eventually
lead to death from liver failure unless liver transplantation is
performed (2, 3). While the role of the immune system in
GVHD and allograft rejection is clear, the immune mecha-
nisms involved in the pathogenesis of PBC and PSC are
obscure, in part because of lack of suitable animal models (2, 3).
Animal models that mimic human immune diseases have
contributed to a better understanding of the pathogenesis of
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these diseases. For example, experimental allergic encephalo-
myelitis (4, 5), type II collagen-induced arthritis (6), and
experimental thyroiditis (5) have all been induced by immu-
nization with exogenous immunogen.
Using highly purified rat cholangiocytes (7) as a source of
antigen, we now describe an experimental approach which
leads to the successful induction of rodent immune cholangitis.
MATERIALS AND METHODS
Rats and Reagents. Twelve-week-old male inbred Wistar/
NHd (RTlU) and Fischer (RTJvl) rats were purchased from
Harlan-Sprague-Dawley. Unless otherwise stated, reagents
were purchased from Sigma.
Cell Isolation. Three weeks after bile duct ligation, hyper-
plastic cholangiocytes were isolated from Wistar or Fischer
rats and purified as previously described (7). Final cholangio-
cyte purity was 75.6% ± 4.2% [n = 8; assessed by staining for
y-glutamyl transpeptidase (yGT), an enzyme which in the liver
is specific for rat cholangiocytes (8)]; contaminating cells were
almost entirely endothelial cells and essentially no hepatocytes
were present. Hepatocytes were isolated from Wistar rats as
described and were .99% pure (9).
Immunization Scheme. Ten million purified hyperplastic
cholangiocytes from Wistar (syngeneic group, n = 12) or
Fischer (allogeneic group, n = 12) rats were emulsified in
Freund's complete adjuvant and injected three times subcu-
taneously into Wistar rats at 14-day intervals. Control Wistar
rats were immunized with either syngeneic hepatocytes (10
million cells per rat; n = 9) or bovine serum albumin (BSA, 100
Atg per rat; n = 9). Five rats in each group received an
additional immunization 28 days after the third immunization.
Histological and Immunohistochemical Evaluation. Ani-
mals from each group were sacrificed 1 week after each
immunization. For histological studies, liver, kidney, colon,
pancreas, and salivary gland were fixed with 10% buffered
Formalin and embedded in paraffin. Sections (5 ,um) were
stained with hematoxylin and eosin, and samples were evalu-
ated under code. The severity of the portal inflammation and
cholangitis was graded from 0 to + + + (1).
To identify the cells infiltrating the portal tracts, fresh frozen
liver sections were stained by the indirect immunoperoxidase
technique. Mouse anti-CD3 monoclonal antibody (IF4, Sero-
tec) was used as a primary antibody (1:200) to detect T cells.
To detect macrophages, B lymphocytes, major histocompati-
bility complex (MHC) class II antigen, or cytokeratin 19
(CK19), mouse monoclonal antibodies MRC OX-41, MRC
OX-33, MRC OX-6 (Serotec), and BA17 (Dako), respectively,
were used as primary antibodies, over a range of dilutions
(1:20-1:200). Horseradish peroxidase (HRPO)-conjugated
goat antibodies to mouse IgM (Tago) for CD3 or HRPO-
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conjugated goat antibodies to mouse IgG (Tago) were used as
second antibodies and developed with aminoethylcarbazole
substrate. In all experiments, negative controls using normal
goat serum instead of primary antibody were employed.
Adoptive Transfer Studies. Spleen cells from either cholan-
giocyte-immunized or BSA-immunized rats were harvested 1
week after the third immunization. Following red blood cell
lysis by hypertonic shock, splenocytes were incubated for 72 hr
in RPMI medium 1640 supplemented with 10% heat-
inactivated fetal bovine serum (HyClone) and Con A at 5
mg/ml. Ten million Con-A-stimulated splenocytes were sub-
sequently injected i.p. into naive (i.e., unimmunized) syngeneic
recipients rats; tissue was harvested 1 week later and processed
as described above.
In Vitro Cytotoxicity Assay. Primary cultures of normal rat
cholangiocytes (NRC-1) served as target cells in the in vitro
cytotoxicity assay and were prepared by a modification of the
method of Yang et al. (10). A rat hepatocyte cell line (BRH)
(ATCC no. CRL1422) was obtained from the American Type
Culture Collection and cultured in Dulbecco's modified Ea-
gle's medium (DMEM)/Ham's F-12 media containing 10%
fetal bovine serum. Their phenotype was confirmed as being
hepatocytic by demonstrating both the presence of glucose-6-
phosphatase, albumin, and aminotransferase (hepatocyte-
specific markers) and the absence of CK19 (cholangiocyte-
specific marker). These cells were cultured (-5 x 105 cells per
well) and served as a control (i.e., noncholangiocyte) target cell.
Con A-Activated Splenocytes. These cells, which serve as
effector cells in the in vitro cytotoxicity assay, were prepared
from cholangiocyte- or BSA-immunized rats as described (11).
Two hours before mixing, target cells (NRC-1 or BRH) were
labeled with 10 ,uCi (1 ,tCi = 37 kBq) of 51Cr (sodium
chromate; Amersham) per 106 cells. After several washings
with cold Hepes-buffered saline, splenocytes (effector cells)
were added to radiolabeled target cells over a range of
effector-to-target ratios (0.1:1 to 100:1) and incubated for 8 hr
at 37°C. The supernatants were collected and detergent (1%
Nonidet P-40) was added to lyse the cells (11, 12); the
supernatant and cell-associated radioactivities were deter-
mined with a y counter, and the cytotoxicity was calculated as
percent release of 51Cr.
Cholangiograms. Cholangiograms were prepared as de-
scribed (12) with livers from rats 1 week after final immuni-
zation with purified cholangiocytes (n = 4) or BSA (n = 3).
Immunoblotting. Immunoblots were performed by the
method of Towbin et al. (13). Briefly, 100 ,ug of protein from
homogenized hyperplastic cholangiocytes or 5 ,ug of human
carbonic anhydrase II (CA-IT) was electrophoresed in an
SDS/10% polyacrylamide gel according to Laemmli (14).
Proteins were then electrophoretically transferred to Nitro
Bind nitrocellulose filters (Micron Separations, Westboro,
MA), and diluted (1:100) preimmune or immune sera from
cholangiocyte-immunized rats was incubated with filters for 1
hr at 37°C. After several washings with 0.3% Tween 20 in
phosphate-buffered saline (PBS), filters were incubated with
alkaline phosphatase-labeled goat anti-rat immunoglobulin
(Cappel) for 1 hr at 37°C and developed with nitroblue
tetrazolium/5-bromo-4-chloro-3-indolyl phosphate substrate.
Serum Liver Enzymes. Serum from each group of rats was
harvested prior to immunization and then weekly for 4 weeks
after initial immunization and stored at -20°C until assayed.
Serum alkaline phosphatase, alanine aminotransferase, yGT,
and direct bilirubin were measured with a clinical auto-
analyzer (Becton Dickinson) set for human parameters, an
approach whose validity we had confirmed with sera from rats
made cholestatic by bile duct ligation.
Statistics. All data were expressed as the mean ± SD.
Statistical analysis of data was performed using the Student t
test, and differences were considered significant at P < 0.05.
RESULTS
Histological Changes Following Immunization with
Cholangiocytes. Liver. One week after the third immunization
with purified hyperplastic cholangiocytes, virtually all portal
tracts in rat liver showed diffuse inflammation consisting
predominantly of mononuclear cells (Fig. 1A), and the infil-
trating mononuclear cells surrounded intrahepatic bile ducts
(Fig. 1B), findings consistent with nonsuppurative cholangitis.
As early as 7 days after initial immunization, cholangiocyte-
immunized animals showed histological evidence of cholangi-
tis which persisted over the first three immunizations (Table
1). However, after a fourth booster immunization, liver spec-
imens showed increased inflammation with destructive cholan-
gitis (Table 1). Surprisingly, the degree of cholangitis did not
differ between the allogeneic and syngeneic immunization
groups. No inflammation was observed in the parenchymal
areas of cholangiocyte-immunized rats. Liver specimens from
BSA- or hepatocyte-immunized rats showed no or minimal
histological abnormalities (Table 1; Fig. 1C).
Nonliver. Tissue specimens from kidney and colon showed
no inflammation after immunization with purified cholangio-
cytes, hepatocytes, or BSA (results not shown). Pancreas,
salivary glands, and extrahepatic bile ducts also showed no
histological abnormalities in any immunization groups (results
not shown).
Immunohistochemistry. Stains for the cholangiocyte-specific
protein CK19 demonstrated unequivocally that after cholan-
giocyte immunization, the structures surrounded by infiltrating
mononuclear cells were bile ducts (Fig. 2A); this was also
observed in biliary epithelia after the booster immunization.
Moreover, immunohistochemistry with specific monoclonal
antibodies revealed that the majority of the portal tract
infiltrates were positive for CD3 and MHC class II antigen
(Fig. 2 B and C) but negative for B-cell and macrophage
epitopes (results not shown).
FIG. 1. Rat liver. (Hematoxylin and eosin.) (A) Liver obtained after immunization with cholangiocytes. (x 120.) (B) Same as A with higher
magnification of portal tract. (x 190.) Note mononuclear cell in bile duct. (C) Liver after immunization with BSA; no inflammation is observed.
(x 120.)
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Table 1. Histological grading of cholangitis
Grade after initial immunization
Day Day Day Day Day 70
Immunogen 7 21 35 70 (booster)
Syngeneic cholangiocytes ++ + + ± 0 +++
Allogeneic cholangiocytes + + ++ + + 0 +++
Hepatocytes + 0 0 0 ±
BSA 0 0 0 0 0
0, No change; +, minimal change; +, mild cholangitis; + +, mod-
erate cholangitis; and +++, severe cholangitis. Each time point
included three animals from each group with the exception of the
hepatocyte and BSA group at day 70 (booster), in which there were two
animals.
Adoptive Transfer Experiments. One week after the i.p. injec-
tion of Con-A-activated splenocytes from cholangiocyte-
immunized rats into naive animals, recipients developed nonsup-
purative cholangitis (Fig. 3A). The inflammation was liver spe-
cific; kidney and colon did not show any histological changes
(results not shown). Immunohistochemistry of liver infiltrates
indicated that these mononuclear infiltrates were predominantly
composed ofT lymphocytes (Fig. 3B) surrounding CK19-positive
bile ducts (Fig. 3C). The adoptive transfer of Con-A-activated
splenocytes from BSA-immunized rats showed no infiltrate in
liver, kidney, or colon (results not shown).
In Vitro Cytotoxicity Assay. 51Cr-labeled NRC-1 or BRH
cells were incubated with splenocytes from cholangiocyte- or
BSA-immunized rats to test whether the splenocytes were
directly cytotoxic for the radiolabeled target cells. Splenocytes
from cholangiocyte-immunized rats caused lysis of 5tCr-
labeled NRC-1 cells in a dose-dependent fashion (Fig. 4A).
This effect was cell specific-that is, splenocytes from cholan-
giocyte-immunized rats did not cause lysis of 51Cr-labeled
BRH cells (Fig. 4B). Splenocytes from BSA-immunized rats
caused no increased lysis of 51Cr-labeled NRC-1 or BRH cells
over the same range of effector-to-target ratios (Fig. 4).
Cholangiograms. No abnormalities were observed on chol-
angiograms of rats immunized with BSA (Fig. 5A). In contrast,
after immunization with cholangiocytes, cholangiograms
showed tortuous intrahepatic ducts and localized areas of duct
ectasia (Fig. SB). No abnormalities were observed in the
extrahepatic ducts of either group.
Immunoblotting. As shown in Fig. 6A, sera from cholan-
giocyte-immunized rats detected several protein bands on
immunoblots of cholangiocyte proteins which were not de-
tected by preimmune sera. Additional experiments indicated
that the humoral response included antibodies against CA-TI,
an antigen found in liver uniquely on cholangiocytes (Fig. 6B).
These antibodies were absent from preimmune sera. While no
distinct band was observed at 32.5 kDa in lane 2 of Fig. 6A





FIG. 2. Immunohistochemistry from liver specimen obtained from
a cholangiocyte-immunized rat. (x 120.) (A) Anti-CK19 antibody
(BA17) staining shows that the interlobular bile duct is surrounded by
inflammatory infiltrates. (B) Anti-CD3 (IF4) staining shows infiltrates
consist primarily of T cells. (C) Some of these infiltrates are positive
for MHC class II protein, suggesting the presence of activated T cells.
ficient material for detection or differential glycosylation of
native and purified CA-IT.
Serum Enzyme Assays. Serial levels of serum liver enzymes,
including alkaline phosphatase, alanine aminotransferase, and
yGT, and total bilirubin did not show any significant change
throughout the experimental period in any immunization
group (data not shown).
FIG. 3. Histology and immunohistochemistry from adoptive transfer experiments. (A) Liver from rat transferred with cholangiocyte-immunized
splenic lymphocytes. Note mononuclear cells are causing cholangitis around interlobular bile duct. (Hematoxylin and eosin; X120.) (B and C)
Anti-CD3 (IF4) (B) and anti-CK19 (BA17) (C) staining from same animal. (x 120.) These serial sections show that the bile duct is surrounded
by CD3-positive T cells.
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FIG. 4. In vitro cytotoxicity assays. Results are mean + SD; n = 3.
(A) Syngeneic 5'Cr-labeled cultured cholangiocytes were used as
target cells, and splenic lymphocytes from cholangiocyte-immunized
rats or BSA-immunized rats were mixed in various effector-to-target
cell ratios. *, Splenic lymphocytes from cholangiocyte-immunized rats
show significantly higher cytotoxicity compared with that of BSA-
immunized rats (P < 0.05). (B) 51Cr-labeled hepatocyte cell line as
target cells. Splenic lymphocytes from neither cholangiocyte-
immunized nor BSA-immunized animals show cytotoxicity.
DISCUSSION
We describe and characterize an animal model of immune
cholangitis with similarities to several immune-mediated
cholangiopathies. Following immunization with rat cholangio-
cytes, inflammation developed in the liver in an organ-specific
fashion and consisted of mononuclear cells, composed pre-
dominantly of T lymphocytes, infiltrating portal tracts and
surrounding bile ducts. Furthermore, adoptive transfer of
unfractionated Con-A-stimulated spleen cells from cholangio-
cyte-immunized rats into naive recipients produced a cholan-
gitis similar to that observed after primary immunization.
Splenocytes from rats immunized with cholangiocytes showed
selective and dose-dependent in vitro cytotoxicity against
cholangiocytes. Immunization with rat cholangiocytes also led
to the development of cholangiocyte-specific antibodies in the
serum of immunized animals. Finally, immunization with
cholangiocytes caused cholangiographic evidence of distortion
and tortuosity of the intrahepatic biliary ductal system. These
results establish and provide initial characterization of a
rodent model of immune-mediated cholangitis.
Immunization with cholangiocytes leads to portal tract
inflammation predominantly composed of T lymphocytes; B
cells, neutrophils, and macrophages appear to be absent. These
results suggest that the T-cell infiltrates are reacting to cholan-
giocyte antigens. Two sets of experiments support this idea. First,
mitogen-activated splenocytes from cholangiocyte-immunized
animals, but not from control-immunized animals, caused spe-
cific, dose-dependent cytolysis of primary cultures of normal rat
cholangiocytes, but not rat hepatocytes. Of relevance, others have














FIG. 6. (A) Immunoblots for detecting crude cholangiocyte protein
by using pooled sera from preimmune animals (lane 1) and those from
cholangiocyte-immunized animals (lane 2). While equal amounts (20
,ug) of protein extracted from hyperplastic cholangiocytes were loaded
and identical dilutions of sera (1:100) were used, only immune sera
show several reactive proteins, ranging from 19 to 120 kDa. (B)
Immunoblots for detecting CA-II. Human CA-II (5 jig) was added
prior to electrophoresis and immunoblotting. Immune sera (lane 2),
but not preimmune sera (lane 1), showed reaction product of the
expected molecular size (arrow).
from healthy controls have cytotoxic activity against cholangio-
cytes (15). Second, the ability to demonstrate portal tract inflam-
mation following the adoptive transfer of mitogen-stimulated
splenocytes from cholangiocyte-immunized animals into naive
recipients supports the cellular immune reactivity against cholan-
giocytes. Aberrant MHC class II expression by bile duct epithelial
cells is well described in human cholangiopathies (3). While MHC
class II expression by biliary epithelia was not observed in the
model, the expression ofMHC class II antigen by cells infiltrating
the portal tracts is consistent with the possibility that they are
activated T cells. The presence of T-cell-predominant infiltrates
in the portal tracts of patients with PBC is well recognized (16).
Not surprisingly, immunization with cholangiocytes also led
to the development of serum antibodies which react against
several cholangiocyte proteins. The identities of these antigens
are unknown; however, one of these antibodies appears to be
against CA-TI, which has been reported to be present in the
sera of patients with autoimmune diseases (17). More recently,
it has been shown that, in patients with immune-mediated liver
diseases (18), CA-Il is expressed only by cholangiocytes in liver
(19). However, the significance of as well as the mechanisms
involved in the production of these antibodies following
cholangiocyte immunization is unclear.
Several features observed in our model of rodent immune
cholangitis contrast with abnormalities seen in the human
immune cholangiopathies. First, the inflammation observed in
our model is self-limited. In addition, the portal tract inflam-
FIG. 5. Representative cholan-
giograms of BSA-immunized (A)
and cholangiocyte-immunized (B)
rats. The BSA-immunized rat
shows a normal-appearing intrahe-
patic biliary tree. The cholangio-
cyte-immunized rat shows tortuous
intrahepatic ducts and localized ar-
eas of ectasia.
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mation is mild to moderate, and no enzyme abnormalities were
observed. These results likely reflect several variables, includ-
ing the immunization scheme. The limited nature of the
immune cholangitis might also be explained by the presence of
a negative-feedback phenomenon, such as clonal elimination
of autoreactive lymphocytes or apoptosis, the lack of which
might account for the progressive immune cholangitis ob-
served in human diseases. Manipulation of the immunization
regimen-including assessment of other sources of T cells
(e.g., mesenteric lymph nodes or liver)-and further purifica-
tion and characterization of key cholangiocyte antigens might
alter the inflammatory response to more closely mimic the
destructive processes that characterize the human immune
cholangiopathies.
Other animal models of human autoimmune disease, such as
experimental allergic encephalomyelitis (EAE) and arthritis
induced by type-II collagen, have similarities with our immune
cholangitis model. Experimental animals develop organ-
specific inflammation consisting predominantly of T lympho-
cytes following active immunization with exogenous proteins.
In both models, antigen-specific T-cell clones have been
established and T cells have been proven to play a central role
in the development of disease-specific inflammation. Also,
adoptive transfer of the inflammation and direct cytotoxicity
toward the target cells has been reported in EAE (20).
Initially, animals were immunized with allogeneic cholangio-
cytes to maximize the host immunological response. Since normal
cholangiocytes express MHC class I, but not MHC class II,
molecules, we were surprised that a greater degree of portal tract
inflammation was not observed with allogeneic than with synge-
neic immunization. This observation suggests that our immuni-
zation protocol breaks tolerance to self-cholangiocytes.
Several other animal models of cholangitis have been re-
ported. For example, cholangitis was induced after surgical
construction of self-filling blind loops of intestine, which leads
to bacterial overgrowth (12). The findings support an associ-
ation between intestinal inflammation and hepatobiliary dis-
eases, and they may help to explain why the vast majority of
patients with PSC have associated inflammatory bowel disease
(3). However, an immunologically mediated mechanism seems
unlikely because immunosuppressive agents (e.g., cyclosporin
A, methotrexate, and prednisone) fail to prevent hepatobiliary
injury in this model (21). Moreover, the portal tract infiltrate
in this model includes neutrophils, and it has not been char-
acterized further. Another model of cholangitis is the murine
model of GVHD (22). Although this rodent model clearly
mimics human GVHD and leads to T-cell-predominant portal
tract infiltrates, the relationship between this inflammation
and the immune cholangitis observed in other cholangiopa-
thies, such as PBC, is still speculative. Moreover, the inflam-
matory infiltrate which characterizes the model of GVHD is
the product, not of active immunization with cholangiocytes,
but of seeding irradiated mice with allogeneic lymphocytes.
Nevertheless, this model supports the concept that an alter-
ation in the immune system of rodents can result in cholangitis.
Two reports have previously described the induction of cholan-
gitis in animals after injection of potential biliary antigens
derived from crude rat liver (23) or rabbit gallbladder (24)
homogenates. These models have not been studied further,
possibly because they were poorly reproducible, and/or the
putative antigens were not derived from purified cholangiocytes;
moreover, the nature of the cellular infiltrates was not fully
defined. More recently, a model of autoimmune cholangitis in
neonatally thymectomized mice stimulated with biliary antigens
derived from partially purified porcine intrahepatic bile duct cells
was reported (25). In these last three reports (23-25), investiga-
tors did not perform adoptive transfer experiments and did not
characterize the specificity and direct cytotoxicity of the lympho-
cytes purported to be involved in the inflammatory liver infiltrate,
since techniques for primary culture of rodent cholangiocytes as
target cells were not available to them. By establishing primary
cultures of rat cholangiocytes in our laboratory, we were able to
utilize a unique tool to directly demonstrate cytotoxicity by
sensitized lymphocytes.
The specific details and molecular mechanisms involved in the
development of immune cholangitis in our model remain to be
elucidated. We speculate that cholangiocyte antigens, which are
normally sequestered within intracellular compartments, are
processed by antigen-presenting cells after exposure during the
immunization period; indeed, on the basis of recent data from our
group (26), we infer that the cholangiocyte itself has the capacity
to present exogenous antigens. Presentation of such antigens in
conjunction with MHC class II proteins to CD4-positive T
lymphocytes could initiate release of cytokines, leading to anti-
body production and the recruitment of cytotoxic T lymphocytes
to biliary epithelia. While this proposed sequence of events is
currently hypothetical, the availability of a reproducible model of
immune cholangitis such as described by us will allow the exper-
imental dissection of this paradigm.
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